These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E; Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851 [TBL] [Abstract][Full Text] [Related]
9. The state of periprocedural antiplatelet therapy after recent trials. Desai NR; Bhatt DL JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450 [TBL] [Abstract][Full Text] [Related]
10. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
11. Ticagrelor: a novel reversible oral antiplatelet agent. Nawarskas JJ; Clark SM Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670 [TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
13. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
17. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470 [TBL] [Abstract][Full Text] [Related]
19. Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. Armani AM Crit Pathw Cardiol; 2010 Dec; 9(4):199-202. PubMed ID: 21119337 [TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S; Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]